The cancer stem cell (CSC) hypothesis is an attractive model to account for the functional heterogeneity that is commonly observed in solid tumours. It proposes a hierarchical organization of cells within the tumour, in which a subpopulation of stem-like cells is responsible for sustaining tumour growth.
The first evidence for CSCs came from acute myeloid leukaemia. There is now increasing evidence for CSCs in a variety of solid tumours (both mouse and human), provided through transplantation studies using prospectively isolated tumour cells.
The frequency of CSCs in solid tumours is highly variable, reflecting biological variation as well as technical issues. Technical issues include the purity of solid tumour cell fractionation, the requirement for more definitive markers and the challenges associated with xenotransplantation. Ultimately it will be necessary to study CSCs and potential heterogeneity within this population at a clonal level through 'cell tagging'.
Not all solid tumours will follow the CSC model of heterogeneity. Some may conform to the clonal evolution model, in which a dominant population of proliferating cells drives tumorigenesis.
Metastatic CSCs may exist, with properties distinct from primary CSCs.
The concept of CSCs has significant clinical implications: CSCs have been shown to be more resistant to chemotherapy and radiotherapy.
Recent reports, primarily for haematopoietic malignancies, suggest that CSCs can be selectively targeted without ablating normal stem cell function.
Solid tumours are an enormous cancer burden and a major therapeutic challenge. The cancer stem cell (CSC) hypothesis provides an attractive cellular mechanism to account for the therapeutic refractoriness and dormant behaviour exhibited by many of these tumours. There is increasing evidence that diverse solid tumours are hierarchically organized and sustained by a distinct subpopulation of CSCs. Direct evidence for the CSC hypothesis has recently emerged from mouse models of epithelial tumorigenesis, although alternative models of heterogeneity also seem to apply. The clinical relevance of CSCs remains a fundamental issue but preliminary findings indicate that specific targeting may be possible.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Cancer Cell International Open Access 21 July 2022
Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade
British Journal of Cancer Open Access 28 April 2022
Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis
Nature Communications Open Access 16 March 2022
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Heppner, G. H. & Miller, B. E. Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev. 2, 5–23 (1983).
Southam, C. M. & Brunschwig, A. Quantitative studies of autotransplantation of human cancer. Cancer 14, 971–978 (1961).
Furth, J. & Kahn, M. C. The transmission of leukemia in mice with a single cell. Am J. Cancer 31, 276–282 (1937).
Hewitt, H. B. Studies of the dissemination and quantitative transplantation of a lymphocytic leukaemia of CBA mice. Br. J. Cancer 12, 378–401 (1958).
Hamburger, A. W. & Salmon, S. E. Primary bioassay of human tumor stem cells. Science 197, 461–463 (1977).
Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med. 3, 730–737 (1997).
Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001).
Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23–28 (1976). A seminal paper describing the clonal evolution of tumour cell populations involving stepwise selection of cells through the acquisition of genetic changes.
Campbell, L. L. & Polyak, K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6, 2332–2338 (2007).
Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648 (1994).
Barabe, F., Kennedy, J. A., Hope, K. J. & Dick, J. E. Modeling the initiation and progression of human acute leukemia in mice. Science 316, 600–604 (2007). This study reveals that leukaemia stem cells have the potential to evolve with time from a primitive cell type to one containing rearranged immunoglobulin H genes. One implication of this work is that CSCs themselves may be subject to clonal evolution.
Clark, E. A., Golub, T. R., Lander, E. S. & Hynes, R. O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406, 532–535 (2000).
Huntly, B. J. et al. MOZ–TIF2, but not BCR–ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587–596 (2004).
Krivtsov, A. V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9. Nature 442, 818–822 (2006).
Somervaille, T. C. & Cleary, M. L. Identification and characterization of leukemia stem cells in murine MLL–AF9 acute myeloid leukemia. Cancer Cell 10, 257–268 (2006).
Cozzio, A. et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 17, 3029–3035 (2003).
Chen, W. et al. Malignant transformation initiated by Mll–AF9: gene dosage and critical target cells. Cancer Cell 13, 432–440 (2008).
Jamieson, C. H. et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657–667 (2004).
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003). This paper provides the first description of the prospective purification of tumour-initiating cells from a solid malignancy, breast cancer.
Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004). The first demonstration of CSCs in brain tumours through the use of CD133 for prospective isolation.
Bao, S. et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66, 7843–7848 (2006).
Beier, D. et al. CD133+ and CD133− glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 67, 4010–4015 (2007).
Taylor, M. D. et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8, 323–335 (2005).
Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006).
Piccirillo, S. G. et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444, 761–765 (2006). These studies reveal that CSCs in gliomas appear to have different properties from the bulk of the population. Reference 24 shows that they are more radioresistant and reference 25 demonstrates that they are responsive to BMP-induced differentiation.
O'Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106–110 (2007).
Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111–115 (2007).
Hermann, P. C. et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313–323 (2007). These findings support the concept of a distinct metastatic CSC with important implications for designing drugs that specifically target the metastatic CSC.
Uchida, N. et al. Direct isolation of human central nervous system stem cells. Proc. Natl Acad. Sci. USA 97, 14720–14725 (2000).
Lee, A. et al. Isolation of neural stem cells from the postnatal cerebellum. Nature Neurosci. 8, 723–729 (2005).
Oshima, Y. et al. Isolation of mouse pancreatic ductal progenitor cells expressing CD133 and c-Met by flow cytometric cell sorting. Gastroenterology 132, 720–732 (2007).
Dalerba, P. et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl Acad. Sci. USA 104, 10158–10163 (2007).
Ginestier, C. et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555–567 (2007).
Wright, M. H. et al. Brca1 breast tumors contain distinct CD44+/CD24− and CD133− cells with cancer stem cell characteristics. Breast Cancer Res. 10, R10 (2008).
Schatton, T. et al. Identification of cells initiating human melanomas. Nature 451, 345–349 (2008). This study reveals that expression of the CSC marker and drug transporter protein ABCB5 in melanoma correlates with clinical progression.
Kern, S. E. & Shibata, D. The fuzzy math of solid tumor stem cells: a perspective. Cancer Res. 67, 8985–8988 (2007).
Bonnefoix, T., Bonnefoix, P., Verdiel, P. & Sotto, J. J. Fitting limiting dilution experiments with generalized linear models results in a test of the single-hit Poisson assumption. J. Immunol. Methods 194, 113–119 (1996).
Zeppernick, F. et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14, 123–129 (2008).
Patrawala, L. et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25, 1696–1708 (2006).
Patrawala, L. et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2− cancer cells are similarly tumorigenic. Cancer Res. 65, 6207–6219 (2005).
Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J. & Maitland, N. J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946–10951 (2005).
Eramo, A. et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15, 504–514 (2008).
Neering, S. J. et al. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood 110, 2578–2585 (2007).
Yilmaz, O. H. et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475–482 (2006).
Kelly, P. N., Dakic, A., Adams, J. M., Nutt, S. L. & Strasser, A. Tumor growth need not be driven by rare cancer stem cells. Science 317, 337 (2007). This paper has challenged the CSC hypothesis, following the observation that three mouse models of leukaemia and lymphoma are maintained by a dominant cell population. The authors posit that xenotransplantation may select for tumour cells capable of surviving in a foreign environment.
Cho, R. W. et al. Isolation and molecular characterization of cancer stem cells in MMTV–Wnt-1 murine breast tumors. Stem Cells 26, 364–371 (2008).
Vaillant, F., Asselin-Labat, M. L., Shackleton, M., Lindeman, G. J. and Visvader, J. E. The mammary progenitor marker CD61/b3integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. (in the press).
Zhang, M. et al. Identification of tumor-initiating cells in a p53 null mouse model of breast cancer. Cancer Res. 68, 4674–4682 (2008).
Malanchi, I. et al. Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling. Nature 452, 650–653 (2008). References 46–49 provide definitive evidence for the existence of CSCs in syngeneic mouse models of mammary and skin tumorigenesis. They further suggest that normal stem and progenitor markers have utility in the identification and isolation of CSCs.
Thiery, J. P. Epithelial–mesenchymal transitions in tumour progression. Nature Rev. Cancer 2, 442–454 (2002).
Mani, S. A. et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc. Natl Acad. Sci. USA 104, 10069–10074 (2007).
Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820–827 (2005).
Yang, Z. F. et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13, 153–166 (2008).
Light, R. W., Erozan, Y. S. & Ball, W. C. Jr. Cells in pleural fluid. Their value in differential diagnosis. Arch. Intern. Med. 132, 854–860 (1973).
Liu, R. et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356, 217–226 (2007).
Shipitsin, M. et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259–273 (2007).
Shmelkov, S. V. et al. CD133 expression is not restricted to stem cells, and both CD133 and CD133 metastatic colon cancer cells initiate tumors. J. Clin. Invest. 118, 2111–2120 (2008).
Carpenter, G. & Cohen, S. Epidermal growth factor. Annu. Rev. Biochem. 48, 193–216 (1979).
Rifkin, D. B. & Moscatelli, D. Recent developments in the cell biology of basic fibroblast growth factor. J. Cell Biol. 109, 1–6 (1989).
Kuperwasser, C. et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA 101, 4966–4971 (2004). This study represents an important step in establishing humanized mouse models for solid tumours, demonstrating that a species-specific stromal niche is important for the growth of human epithelial cells.
Gupta, P. B. et al. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res. 67, 2062–2071 (2007).
Takenaka, K. et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nature Immunol. 8, 1313–1323 (2007).
Shultz, L. D. et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rγnull mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477–6489 (2005).
Galli, R. et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 7011–7021 (2004).
Li, C. et al. Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030–1037 (2007).
Bissell, M. J. & Labarge, M. A. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 7, 17–23 (2005).
Mehta, R. R., Graves, J. M., Hart, G. D., Shilkaitis, A. & Das Gupta, T. K. Growth and metastasis of human breast carcinomas with Matrigel in athymic mice. Breast Cancer Res. Treat. 25, 65–71 (1993).
Henson, B. et al. An orthotopic floor-of-mouth model for locoregional growth and spread of human squamous cell carcinoma. J. Oral Pathol. Med. 36, 363–370 (2007).
Prokhorova, T. A. et al. Teratoma formation by human embryonic stem cells is site-dependent and enhanced by the presence of Matrigel. Stem Cells Dev. 7 Apr 2008 (doi:10.1089/scd.2007.0266).
Marshall, G. P. 2nd, Reynolds, B. A. & Laywell, E. D. Using the neurosphere assay to quantify neural stem cells in vivo. Curr. Pharm. Biotechnol. 8, 141–145 (2007).
Reynolds, B. A. & Rietze, R. L. Neural stem cells and neurospheres — re-evaluating the relationship. Nature Meth. 2, 333–336 (2005). The sphere assay, originally developed for neural cells, has formed an important basis for the development of an in vitro assay to study both normal stem and progenitor cells and tumour-initiating cells in a variety of solid tumours including brain (reference 73) and breast (reference 78).
Kondo, T. & Raff, M. Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. Science 289, 1754–1757 (2000).
Hemmati, H. D. et al. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl Acad. Sci. USA 100, 15178–15183 (2003).
Clement, V., Sanchez, P., de Tribolet, N., Radovanovic, I. & Ruiz i Altaba, A. HEDGEHOG–GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 17, 165–172 (2007).
Diamandis, P. et al. Chemical genetics reveals a complex functional ground state of neural stem cells. Nature Chem. Biol. 3, 268–273 (2007).
Beier, D. et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 68, 5706–5715 (2008).
Yu, F. et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131, 1109–1123 (2007).
Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253–1270 (2003).
Ishikawa, F. et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nature Biotechnol. 25, 1315–1321 (2007).
Ito, K. et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072–1078 (2008).
Shachaf, C. M. et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431, 1112–1117 (2004).
Guzman, M. L. et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105, 4163–4169 (2005).
Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F. & Dick, J. E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nature Med. 12, 1167–1174 (2006).
Krause, D. S., Lazarides, K., von Andrian, U. H. & Van Etten, R. A. Requirement for CD44 in homing and engraftment of BCR–ABL-expressing leukemic stem cells. Nature Med. 12, 1175–1180 (2006).
Lee, J. et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13, 69–80 (2008).
Walkley, C. R. et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor γ deficiency. Cell 129, 1097–1110 (2007).
Calabrese, C. et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69–82 (2007). This study and reference 21 suggest that CSCs in tumours are maintained by an aberrant vascular niche and that glioblastoma CSCs have potent angiogenic activity.
Folkins, C. et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 67, 3560–3564 (2007).
Hambardzumyan, D. et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 22, 436–448 (2008).
Blazek, E. R., Foutch, J. L. & Maki, G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133− cells, and the CD133+ sector is enlarged by hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 67, 1–5 (2007).
Phillips, T. M., McBride, W. H. & Pajonk, F. The response of CD24−/low/CD44+ breast cancer-initiating cells to radiation. J. Natl Cancer Inst. 98, 1777–1785 (2006).
Woodward, W. A. et al. WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl Acad. Sci. USA 104, 618–623 (2007).
Al-Hajj, M. Cancer stem cells and oncology therapeutics. Curr. Opin. Oncol. 19, 61–64 (2007).
Li, X. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst. 100, 672–679 (2008). References 77 and 94 provide evidence for a subpopulation of chemotherapy-resistant cancer-initiating cells in breast cancer patients.
Shafee, N. et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 68, 3243–3250 (2008).
Dylla, S. J. et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS ONE 3, e2428 (2008).
Todaro, M. et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1, 389–402 (2007).
Johnstone, R. W., Cretney, E. & Smyth, M. J. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93, 1075–1085 (1999).
Blair, A., Hogge, D. E., Ailles, L. E., Lansdorp, P. M. & Sutherland, H. J. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 89, 3104–3112 (1997).
Jordan, C. T. et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777–1784 (2000).
Chang, H. H., Hemberg, M., Barahona, M., Ingber, D. E. & Huang, S. Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature 453, 544–547 (2008).
Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunol. 5, 738–743 (2004).
Kleinsmith, L. J. & Pierce, G. B., Jr. Multipotentiality of single embryonal carcinoma cells. Cancer Res. 24, 1544–1551 (1964).
Lowe, S. W. & Sherr, C. J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13, 77–83 (2003).
Molofsky, A. V., He, S., Bydon, M., Morrison, S. J. & Pardal, R. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev. 19, 1432–1437 (2005).
Pardal, R., Molofsky, A. V., He, S. & Morrison, S. J. Stem cell self-renewal and cancer cell proliferation are regulated by common networks that balance the activation of proto-oncogenes and tumor suppressors. Cold Spring Harb. Symp. Quant. Biol. 70, 177–185 (2005).
Leung, C. et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428, 337–341 (2004).
Reya, T. & Clevers, H. Wnt signalling in stem cells and cancer. Nature 434, 843–850 (2005).
He, X. C., Zhang, J. & Li, L. Cellular and molecular regulation of hematopoietic and intestinal stem cell behavior. Ann. N. Y. Acad. Sci. 1049, 28–38 (2005).
Haramis, A. P. et al. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science 303, 1684–1686 (2004).
He, X. C. et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt–β-catenin signaling. Nature Genet. 36, 1117–1121 (2004).
Ming Kwan, K., Li, A. G., Wang, X. J., Wurst, W. & Behringer, R. R. Essential roles of BMPR-IA signaling in differentiation and growth of hair follicles and in skin tumorigenesis. Genesis 39, 10–25 (2004).
Ayyanan, A. et al. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc. Natl Acad. Sci. USA 103, 3799–3804 (2006).
Shackleton, M. et al. Generation of a functional mammary gland from a single stem cell. Nature 439, 84–88 (2006).
Zhao, C. et al. Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12, 528–541 (2007).
Mizrak, D., Brittan, M. & Alison, M. R. CD133: molecule of the moment. J. Pathol. 214, 3–9 (2008).
Prince, M. E. et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA 104, 973–978 (2007).
Wu, C. et al. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res. 67, 8216–8222 (2007).
Clarke, M. F. et al. Cancer stem cells — perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66, 9339–9344 (2006).
Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821–5828 (2003).
We sincerely apologize to those authors whose papers we could not cite owing to space constraints. We are grateful to J. Adams for discussions and P. Maltezos for expert help with the figures. This work was supported by the Victorian Breast Cancer Research Consortium and the National Health and Medical Research Council (Australia). We also acknowledge support from the National Breast Cancer Foundation (Australia), the Susan G. Komen Breast Cancer Foundation, the US Department of Defense, the Australian Stem Cell Centre and the Australian Cancer Research Foundation.
National Cancer Institute
National Cancer Institute Drug Dictionary
- Tumour xenograft
Owing to the limited amount of tumour material it is necessary to establish xenografts. This involves limited passaging of the tumour, preferably in an orthotopic location, in immunocompromised mice such as NOD-SCID strains. The validity of using xenografts has been documented for many different tumour types. The engraftment rate can be variable, dependent on the tumour type.
- Non-adherent sphere
Both normal and cancerous cells from numerous organs can be expanded as non-adherent sphere-like cellular aggregates in serum-free media containing EGF and FGF2.
About this article
Cite this article
Visvader, J., Lindeman, G. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8, 755–768 (2008). https://doi.org/10.1038/nrc2499
Cancer Cell International (2022)
Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer
BMC Cancer (2022)
Egyptian Journal of Medical Human Genetics (2022)
Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade
British Journal of Cancer (2022)
Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis
Nature Communications (2022)